550 related articles for article (PubMed ID: 28445992)
1. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
2. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
3. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.
Marek L; Ware KE; Fritzsche A; Hercule P; Helton WR; Smith JE; McDermott LA; Coldren CD; Nemenoff RA; Merrick DT; Helfrich BA; Bunn PA; Heasley LE
Mol Pharmacol; 2009 Jan; 75(1):196-207. PubMed ID: 18849352
[TBL] [Abstract][Full Text] [Related]
5. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
7. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
Pietras RJ; Márquez DC; Chen HW; Tsai E; Weinberg O; Fishbein M
Steroids; 2005; 70(5-7):372-81. PubMed ID: 15862820
[TBL] [Abstract][Full Text] [Related]
9. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.
Hershberger PA; Vasquez AC; Kanterewicz B; Land S; Siegfried JM; Nichols M
Cancer Res; 2005 Feb; 65(4):1598-605. PubMed ID: 15735050
[TBL] [Abstract][Full Text] [Related]
10. G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1.
Liu C; Liao Y; Fan S; Tang H; Jiang Z; Zhou B; Xiong J; Zhou S; Zou M; Wang J
Med Oncol; 2015 Apr; 32(4):104. PubMed ID: 25744245
[TBL] [Abstract][Full Text] [Related]
11. Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.
Delpuech O; Rooney C; Mooney L; Baker D; Shaw R; Dymond M; Wang D; Zhang P; Cross S; Veldman-Jones M; Wilson J; Davies BR; Dry JR; Kilgour E; Smith PD
Mol Cancer Ther; 2016 Nov; 15(11):2802-2813. PubMed ID: 27550940
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.
Fischer H; Taylor N; Allerstorfer S; Grusch M; Sonvilla G; Holzmann K; Setinek U; Elbling L; Cantonati H; Grasl-Kraupp B; Gauglhofer C; Marian B; Micksche M; Berger W
Mol Cancer Ther; 2008 Oct; 7(10):3408-19. PubMed ID: 18852144
[TBL] [Abstract][Full Text] [Related]
13. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
14. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma.
Niikawa H; Suzuki T; Miki Y; Suzuki S; Nagasaki S; Akahira J; Honma S; Evans DB; Hayashi S; Kondo T; Sasano H
Clin Cancer Res; 2008 Jul; 14(14):4417-26. PubMed ID: 18579664
[TBL] [Abstract][Full Text] [Related]
16. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
Fisher MM; SenthilKumar G; Hu R; Goldstein S; Ong IM; Miller MC; Brennan SR; Kaushik S; Abel L; Nickel KP; Iyer G; Harari PM; Kimple RJ; Baschnagel AM
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):793-803. PubMed ID: 32298810
[TBL] [Abstract][Full Text] [Related]
18. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
[TBL] [Abstract][Full Text] [Related]
19. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Garon EB; Pietras RJ; Finn RS; Kamranpour N; Pitts S; Márquez-Garbán DC; Desai AJ; Dering J; Hosmer W; von Euw EM; Dubinett SM; Slamon DJ
J Thorac Oncol; 2013 Mar; 8(3):270-8. PubMed ID: 23399957
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
